On November 1, 2017, CMS announced that it is in fact cutting Medicare Part B reimbursement for 340B drugs to the tune of $1.6 billion. To be accurate, what CMS announced is its intent to finalize proposed rule changes to the Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems Quality Reporting Program. As part of the rule changes, CMS will be implementing, with minor tweaks, the proposal it first announced last summer to significantly reduce Medicare Part B reimbursement for 340B drugs paid to hospitals and ambulatory surgical centers. The full text of the final rule with commentary is available now and will be published in the Federal Register on November 13th. The reimbursement reduction, and other changes relative to 340B, are scheduled to go into effect on January 1, 2018.
The rule only impacts Medicare Part B reimbursement for 340B, and no other government or private payor reimbursement. Still, the change will have major repercussions in the 340B world. When the proposed rule was first announced, I posted answers to a myriad of questions about the proposal and its potential impact on 340B covered entities. With the “rule” now in final form, I can revisit some of those questions and answers. Continue Reading CMS Finalizes Medicare Part B Reimbursement Cut for 340B – What Does it Mean?